Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Infectious Diseases
Volume 8 (1997), Issue 3, Pages 157-160
Brief Report

Reduction in the Nephrotoxicity of Amphotericin B when Administered in 20% Intralipid

Suzette Salama and Coleman Rotstein

Departments of Pharmacy and Medicine, The Henderson General Division, Hamilton Civic Hospitals and the Division of Infectious Diseases, McMaster University, Hamilton, Ontario, Canada

Received 18 March 1996; Accepted 14 November 1996

Copyright © 1997 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The administration of amphotericin B (AmB) is often limited by the development of nephrotoxicity. In a pilot crossover trial, aqueous AmB followed by a new preparation of a mixture of AmB with 20% intralipid (AmB-IL) was administered to 10 immunocompromised patients for systemic fungal infections caused by Candida species. Mean total dose and duration of therapy with AmB-IL exceeded that of aqueous AmB (649±165 mg versus 394±105 mg, P=0.061 and 13.2±2.5 days versus 9±2.1 days, P=0.31). However, mean creatinine clearance of the patients rose during AmB-IL therapy by 10.7±7.7 mL/min (P=0.03). AmB-IL warrants further investigation to assess its stability and efficacy for treating serious fungal infections.